ClinicalTrials.Veeva

Find clinical trials for Ovarian Cancer in Los Angeles, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Los Angeles, CA, USA:

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

The purpose of this clinical study is to confirm the utility of chemosensitivity (ChemoID) tumor testing on cancer stem cells as a predictor ...

Active, not recruiting
Recurrent Ovarian Carcinoma
Platinum-resistant Ovarian Cancer
Diagnostic Test: ChemoID Assay
Drug: Standard Chemotherapy

Phase 3

Cordgenics

Los Angeles, California, United States and 7 other locations

The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated w...

Active, not recruiting
Ovarian Neoplasms
Ovarian Cancer
Biological: Vigil
Other: Placebo

Phase 2

Gradalis

Irvine, California, United States and 25 other locations

bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and prima...

Enrolling
Primary Peritoneal Cancer
Platinum-refractory Ovarian Cancer
Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin
Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin

Phase 3

Genelux

Duarte, California, United States and 22 other locations

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Durvalumab placebo
Drug: Bevacizumab

Phase 3

AstraZeneca
AstraZeneca

Los Angeles, California, United States and 213 other locations

in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Drug: carboplatin
Drug: carboplatin

Phase 2

AstraZeneca
AstraZeneca

West Hollywood, California, United States and 41 other locations

mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in...

Invitation-only
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Pegylated Liposomal Doxorubicin + SL-172154
Drug: Mirvetuximab + SL-172154

Phase 1

Shattuck Labs

Duarte, California, United States and 23 other locations

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

Los Angeles, California, United States and 21 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Los Angeles, California, United States and 176 other locations

of SON-1010 in combination with atezolizumab administered to patients with advanced solid tumors (Part 1) and patients with Platinum-resistant Ovarian...

Enrolling
Platinum-resistant Ovarian Cancer
Advanced Solid Tumor
Biological: SON-1010

Phase 1, Phase 2

Sonnet BioTherapeutics

Santa Monica, California, United States and 3 other locations

positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...

Active, not recruiting
Primary Peritoneal Cancer
High Grade Ovarian Cancer
Drug: Mirvetuximab soravtansine
Drug: Carboplatin

Phase 2

ImmunoGen
ImmunoGen

Los Angeles, California, United States and 70 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems